BH Medical Products Co., Ltd. was established in 2003, specializing in the production and sales of infection control and nursing care products widely used in medical, nursing, dental, beauty, tattoo, and veterinary clinic industries.

From its inception, the BH Medical has implemented a long-term "3 Bases 5 Centers" strategic plan.

The "3 Bases" are located in Gaochun District of Nanjing City Jiangsu Province, Zhonglou District of Changzhou City and Hongqiao Development Zone of Taixing City. These three production bases cover a total area of approximately 70,000 square meters, including 50,000 square meters of production workshops (comprising 3,000 square meters of 100,000-class purification workshops, 20,000 square meters of 300,000-class clean rooms, and 27,000 square meters of standard workshops), 450 square meters of laboratories and over 20,000 square meters of warehouses.

The "5 Centers" are located in Changzhou (China), Sacramento (USA), Adelaide (Australia) , Toronto(Canada) and Valencia (Spain). HMT Medical runs a 3,000-square-meter operation center in Changzhou; NuCare runs a 1,500-square-meter operation center in Sacramento; NuMedical runs a 6,000-square-meter operation center in Adelaide. BH Medical Canada operates a sales office in Toronto, Canada. NuMedical Spain will have its operation center in 2026.

Since its establishment, the BH Medical has adhered to scientific management and honest business practices. Through strategic market insights, rigorous quality standards, and diversified product development, it has gained high recognition from domestic and international clients.

The BH Medical maintains a robust quality management team that utilizes laboratory facilities for R&D, patent acquisition, and real-time production monitoring. It has implemented ISO13485 and QSR820 medical device quality management systems, obtaining numerous Class I and II medical device certifications including EU CE, Japan QMS, US FDA, Chinese FDA, and Australia TGA.

Committed to its "3 Bases 4 Centers" strategy, the Group continues to expand global presence. It will increase R&D investment in infection control products and establish additional operation centers worldwide to complete its global network layout.